A Study to Find an Efficacious and Safe Dose of CHF10067 in Participants With Idiopathic Pulmonary Fibrosis

על הניסוי

The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF). It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study. A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.

צפו ב-NCT07516951 ב-ClinicalTrials.gov ←

קישורים קשורים